ClinicalTrials.Veeva

Menu
A

Asan Medical Center | Clinical Trial Center

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Atezolizumab
Paclitaxel
Carboplatin
Bevacizumab
Cisplatin
Gemcitabine
Trastuzumab
Docetaxel
Capecitabine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

598 of 2091 total trials

(Peak) a Phase 3 Randomized Trial of CGT9486+Sunitinib Vs. Sunitinib in Subjects with Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll...

Enrolling
Metastatic Cancer
Advanced Gastrointestinal Stromal Tumors
Drug: CGT9486 plus sunitinib
Drug: CGT9486

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: Placebo
Drug: BLU-5937

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with chemotherapy can treat certain gastrointestinal (GI) cancers. The GI can...

Enrolling
Biliary Tract Cancer
Pancreatic Ductal Adenocarcinoma
Drug: Rescue medication
Biological: Sacituzumab tirumotecan

Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harde...

Enrolling
Pulmonary Arterial Hypertension
Biological: Sotatercept
Biological: Background PAH Therapy

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (I...

Active, not recruiting
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Drug: Domvanalimab
Drug: Zimberelimab

This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV Trial to evaluate the efficacy and safety of Choline Alfoscerate compa...

Not yet enrolling
Vascular Cognitive Impairment
Drug: Placebo of Choline Alfoscerate 400mg
Drug: Choline Alfoscerate 400mg

This is a randomized, double-blind, multi-center, therapeutic confirmatory, phase 3 trial to evaluate the efficacy and safety of CKD-391 and CKD-331...

Enrolling
Primary Hypercholesterolemia
Drug: D086
Drug: Placebo (for CKD-331)

The purpose of this study is to determine whether Fractional flow reserve (FFR, (coronary pressure wire-based index for assessing the ischemic potent...

Active, not recruiting
Coronary Disease
Coronary Stenosis
Procedure: CABG
Device: Resolute Integrity Stent

This randomized controlled confirmatory study will be evaluating an mobile application, MORA Cure (ETH-01K), owned by EverEx, Inc., to examine safety...

Active, not recruiting
Patellofemoral Pain Syndrome
Device: MORA Cure
Other: Treatment as Usual

This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment...

Active, not recruiting
T-cell Lymphoma
Drug: CPI-818
Locations recently updated

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation...

Enrolling
Waldenström Macroglobulinemia
Marginal Zone Lymphoma
Drug: BGB-16673
Locations recently updated

This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinet...

Enrolling
Advanced Pancreatic Ductal Adenocarcinoma
Advanced Non-squamous Non-small-cell Lung Cancer
Drug: Cetuximab
Drug: BGB-53038

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

Enrolling
Advanced Breast Cancer
Drug: Elacestrant
Drug: MEN2312

Researchers are looking for a better way to treat people who have advanced solid tumors including a specific kind of lung cancer (non-small cell lung...

Enrolling
Advanced Solid Tumors
Non-small Cell Lung Cancer
Drug: BAY2862789

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have c...

Enrolling
Progressive Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Drug: BI 1015550

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Active, not recruiting
Crohn's Disease
Drug: Mirikizumab

This study aims to assess objective response rate of modified FOLFIRINOX in advanced urachaus cancer.Patients with locally advanced, recurrent, or me...

Enrolling
Urachal Cancer
Drug: FOLFIRINOX
New

This sponsor-initiated, randomized controlled clinical trial aims to demonstrate the clinical efficacy of RUS NE Surgical Navigation System in patien...

Begins enrollment this month
Renal Tumors
Device: RUS NE

To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free sur...

Active, not recruiting
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Drug: Fuzuloparib Placebo, Abiraterone acetate and Prednisone
Drug: Fuzuloparib , Abiraterone acetate and Prednisone

The purpose of this study is to evaluate the safety and tolerability of:* casdatifan when taken alone in participants with advanced solid tumor malig...

Enrolling
Solid Tumors
Clear Cell Renal Cell Carcinoma
Drug: Zimberelimab
Drug: casdatifan

Trial sponsors

A
Roche logo
S
Pfizer logo
Merck Sharp & Dohme (MSD) logo
Janssen (J&J Innovative Medicine) logo
AbbVie logo
Boehringer Ingelheim logo
Amgen logo
Lilly logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems